RCS - IXICO plc - IXICO to Present at SCA & ARCA Global Conference

IXICOAnnouncement

19/10/2020 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20201019:nRSS3949Ca

RNS Number : 3949C  IXICO plc  19 October 2020

 

This is an RNS Reach announcement and the information contained is not
considered to be material or to have a significant impact on management's
expectations of the Group's performance. RNS Reach is an investor
communication service aimed at assisting listed and unlisted (including AIM
quoted) companies to distribute non-regulatory news releases into the public
domain. Information required to be notified under the AIM Rules for Companies,
Market Abuse Regulation or other regulation would be disseminated as an RNS
regulatory announcement and not on RNS Reach.

 

IXICO plc

("IXICO" or the "Company")

 

IXICO to Present at SCA & ARCA Global Conference

 

IXICO plc (AIM: IXI), the AI data analytics company delivering insights in
neuroscience, announces that Dr Robin Wolz, Senior Vice President of Science
& Innovation at IXICO, will present on the industry panel at the virtual
SCA & ARCA Global Conference, taking place on 19-21 October 2020.

 

The SCA & ARCA Global Conference brings together two initiatives that
focus on ataxia, which is the loss of coordination of voluntary muscle
movements. This platform allows for  academic and industry leaders,
physicians and companies working in the space to collaborate on developing
future treatments for patients.

 

Autosomal-recessive cerebellar ataxias (ARCA) are a heterogeneous group of
rare degenerative and metabolic genetic diseases recessively inherited and
spinocerebellar ataxias (SCAs) are a group of autosomal dominantly inherited
progressive ataxia disorders. The clinical manifestations of hereditary
ataxias are poor coordination of movement and unsteady gait.

 

Dr Robin Wolz will be presenting on the industry panel on 20 October at 16.20
(BST). The talk is titled: "Challenges and opportunities in the deployment of
volumetric MRI in SCA clinical trials." Additionally, IXICO are supporting the
conference as an official partner of SCA & ARCA Global 2020.

 

Dr Robin Wolz, Senior Vice President, Science & Innovation at IXICO
commented: "Ataxia conditions continue to be a focus for IXICO in its efforts
to provide pioneering technologies to support the advancement of effective
treatments for rare neurological diseases. Our research in imaging analytics
will provide an insight into the best methods for monitoring both the
progression of the disease as well as the potential effect of interventional
treatments."

 

Additional info can be found on the conference website:
http://ataxia-global-initiatives.net/sca-global/conferences/sca-global-2020/
(http://ataxia-global-initiatives.net/sca-global/conferences/sca-global-2020/)
 

 

For further information please contact:

 

 IXICO plc                                           +44 (0)20 3763 7498
 Giulio Cerroni, Chief Executive Officer

 Grant Nash, Chief Financial Officer

 Cenkos Securities PLC (Nominated adviser and sole broker)                 +44 (0)20 7397 8900
 Giles Balleny / Max Gould (Corporate Finance)
 Michael F Johnson / Russell Kerr (Sales)

 Walbrook PR Ltd           Tel: +44 (0) 20 7933 8780 or IXICO@walbrookpr.com
                           (mailto:IXICO@walbrookpr.com)
 Paul McManus / Lianne Cawthorne / Alice Woodings

 

About IXICO

IXICO is dedicated to delivering insights in neuroscience. Our mission is to
transform the progression of our biopharmaceutical clients' neurological
therapeutic pipelines through the application of novel imaging and digital
biomarkers.

 

IXICO's data analytics services are used by the global biopharmaceutical
industry to interpret data from brain scans and digital biosensors to enable
better trial design, site qualification, patient selection and clinical
outcomes. We provide technology-enabled services across all phases of clinical
evaluation. Our integrated digital platform provides a scalable and secure
infrastructure for the capture and analysis of regulatory compliant clinical
data to enable clients to make rapid, better informed decisions. IXICO is also
collaborating with partners to develop new analytical techniques and companion
digital health products targeted at improving patient outcomes.

 

More information is available on www.IXICO.com (http://www.IXICO.com) and
follow us on Twitter @IxicOplc

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAZZMMGRVDGGZM